A Phase III Randomized Trial of Three Antibiotic Regimens to Eradicate Helicobacter Pylori
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 1,859
- 试验地点
- 7
- 主要终点
- To compare 2 experimental antibiotic regimens with a standard 14 day regimen with regard to H. pylori eradication rates at 6 weeks post-randomization.
研究概览
简要总结
The purpose of this study is to compare the effectiveness of three different antibiotic regimens against Helicobacter pylori (H. pylori).
详细描述
Prevention of gastric cancer through eradication of H. pylori is one of the most promising strategies to reduce the global impact of cancer in the near term. Our long-term goal is to prevent gastric cancer by developing and validating an effective, simple, and low-cost approach to eradication of H. pylori. Our immediate goal, therefore, is to conduct a randomized study to compare the effectiveness of three different drug regimens for H. pylori infection. The three study arms are: Standard therapy - 14 day, 3-drug regimen of Lansoprazole, amoxicillin and clarithromycin (PACx14); Concomitant therapy - 5 day, 4-drug regimen of lansoprazole, amoxicillin, clarithromycin, metronidazole (PACMx5); Sequential therapy - 10 day, 4-drug regimen of lansoprazole, amoxicillin for 5 days, followed by lansoprazole, clarithromycin and metronidazole for 5 days (PAx5/PCMx5).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 21 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •positive Urea Breath Test documenting H. pylori infection
- •age 21 - 65 years
- •no known allergies to study drugs
- •only member of household participating in study
- •no known medical conditions (other than H. pylori) that would preclude or require antibiotic therapy
- •patients must be willing to discontinue alcohol use for 15 days (maximum duration of treatment plus one day)
- •patients must be willing to discontinue use of antacids for duration of study treatment
- •patients must not have used proton pump inhibitors (PPI) within 30 days of registration. Patients also must be willing to stop using non-study provided PPIs until the completion of the 6 week follow-up contact.
- •patients must not have been treated with antibiotics for H. pylori in the past and must not have taken any other antibiotics within 30 days of registration.
- •patients must be willing to return for 2 follow-up visits: 6 weeks after randomization following completion of treatment & 1 year after randomization
- •patients must be willing to allow submission of blood for assays of serum markers of bacterial virulence and host genetic susceptibility and environmental factors and provide consent for use of specimens.
排除标准
- •current use of anti-retroviral therapy for HIV or AIDS
- •diagnosed congestive hear failure
- •renal failure requiring dialysis
- •diagnosed hepatic failure resulting in hyperbilirubinemia
- •any current or prior malignancy except: adequately treated basal or squamous cell skin cancer, in situ cervical cancer, adequately treated Stage I or Stage II cancer from which the patient has been disease free for 5 years
- •pregnancy or nursing mothers
研究组 & 干预措施
Arm 1
Standard 14 day, 3-drug regimen
干预措施: PACx14 (Drug)
Arm 2
Concomitant Therapy - 5 day, 4-drug regimen
干预措施: PACMx5 (Drug)
Arm 3
Sequential Therapy - 10 day, 4-drug regimen
干预措施: PAx5/PCMx5 (Drug)
结局指标
主要结局
To compare 2 experimental antibiotic regimens with a standard 14 day regimen with regard to H. pylori eradication rates at 6 weeks post-randomization.
时间窗: week 6 post-randomization
次要结局
- Secondary aims will examine infection rates at 1 year, safety and tolerability of these regimens,& potential differential effects among selected groups.(1 year)